PFE · News · 20261113N
Revenue Performance and Mix
PFIZER INC · 2026-11-13 · Importance 51 · Surprise 60 · In source text
Pfizer reported third-quarter 2026 revenue of $16.58 billion, flat year over year, and adjusted earnings of $0.87 per share. Growth in Eliquis, Padcev, the Vyndaqel family, Nurtec, and Lorbrena was offset by lower sales of COVID-19 products and the Prevnar family. The report also said strong year-to-date commercial performance prompted Pfizer to raise its full-year 2026 revenue and earnings guidance, without specifying the revised amounts.
Key facts
- Pfizer's third-quarter adjusted earnings were $0.87 per share and revenue was $16.58 billion, both flat year over year. source
- Pfizer raised its full-year 2026 revenue and earnings guidance after strong year-to-date commercial performance. source
- Pfizer growth in Eliquis, Padcev, the Vyndaqel family, Nurtec and Lorbrena was offset by lower sales of COVID-19 products and the Prevnar family. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| revenue | unclear | realized | 0.0% | Pfizer's third-quarter adjusted earnings were $0.87 per share and revenue was $16.58 billion, both flat year over year. |